Stereotaxis RF guidewire cleared for peripheral artery disease
This article was originally published in The Gray Sheet
Executive Summary
Stereotaxis' magnetically-tipped, steerable PowerAssert radiofrequency guidewire for crossing chronic total occlusions in the peripheral vasculature will begin a "limited" debut "later this year" to treat peripheral artery disease following FDA market go-ahead, announced Aug. 27. A broader commercial launch will follow, according to the company. The American Heart Association estimates 8 million-12 million people have PAD, the firm states. Clearance provides a "significant new market opportunity" for the firm's Niobe magnetic navigation system, currently used for cardiac electrophysiology procedures, the company notes (1"The Gray Sheet" Aug. 11, 2008, p. 18)
You may also be interested in...
Earnings Roundup: Updates From Quarterly Business Reports
With earnings season in full swing, device firms are disclosing financial results and, in some cases, more details about their future plans. Here are highlights from earnings reports released during the past week
EU Regulatory Assessors Get AI Boost In Reaching Scientific Decisions
The European Medicines Agency is training scientific staff working for the European medicines regulatory network in how to use a new AI-powered search engine that allows them to easily retrieve information on regulatory precedents.
EU Parliament Stricter Than Council On Medicines And Medical Devices Packaging
The EU Parliament's Environment, Public Health and Food Safety committee takes a compromise position with regards to the Packaging and Packaging Waste Directive. Medicines and medical devices should be exempt, but only until 2035, at which point the European Commission should check whether the development of materials and the recycling process have progressed, and may adjust this exemption accordingly.